Sichuan University

Cspc Zhongqi Pharmaceutical Technology (shijiazhuang) Co., Ltd.

Guizhou Bailing Group Pharmaceutical Co., Ltd.

Changzhou Yinsheng Pharmaceutical Co., Ltd.

Westgene Biopharma Co., Ltd

University of Massachusetts

St. Chuan University

Guangxi Wuzhou Pharmaceuticals (group) Co., Ltd.

Sichuan Gooddoctor Pharmaceutical Group Co., Ltd.

Westvac Biopharma Co., Ltd.

Guangzhou Kongque Gene Technology Co. Ltd.

Shenzhen Optimum Biological Technology Co., Ltd

Chengdu Zenitar Biomedical Technology Co., Ltd.

Cspc Zhongqi Pharmaceutical Technology Co., Ltd.

Guangxi Wuzhou Pharmaceuticals Co., Ltd.

Yuquan Wei

Xiawei Wei

Jian Li

Shuhui Chen

Lijuan Chen

Shengyong Yang

Luoting Yu

Xin Tao

Zhenling Wang

Xiangrong Song

Guangping Gao

Charles Z Ding

Guoping Hu

Jianfei Wang

Li Yang

Zhifei Fu

Chunli Shen

Phillip Tai

Rui Li

XiaWei Wei

Yong Peng

Ke Wu

Jia Geng

Youfu Luo

Zhiyao He

Funeng Geng

Guangchao Xu

Li Luo

Shuangyan Tan

Xia Zhao

Zhiwei Zhao

Min Luo

Ke Men

Xueyan Zhang

Gu He

Disclosed is a method for preparing an N-acetyl-D-galactosamine tripolymer precursor. In the preparation of the tripolymer precursor, a compound 4 is prepared by the following steps: adding a compound 3, a 4 Å molecular sieve powder, and a reaction solvent into a reactor; inflating and changing protective gas for 3 times; stirring; firstly adding an enol, followed by slowly dropping trimethylsilyl trifluoromethanesulfonate; after a reaction, quenching the reaction with an alkali solution; and performing extraction, separating liquid, washing, drying, filtration, etc., so as to obtain the compound 4. According to the present disclosure, the problems of various production processes, more times of column chromatography for purification of products accompanied by lower yields in the prior art are solved.

Method for preparing n-acetyl-d-galactosamine tripolymer precursor

The present disclosure relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof, which can be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid.

Ionizable lipids and compositions for nucleic acid delivery

An application of a compound represented by formula (I) and pharmaceutically acceptable salts thereof in preparation of a drug for treating pneumonia.

Application of monocyclic β-lactam compound in pharmacy

This invention belongs to the field of biotechnology, in particular to a mutant double-strand DNA (dsDNA) helicase protein nanopore derived from bovine papillomavirus and its application. The technical problem to be solved by this invention is to overcome the deficiency that the existing small-diameter protein nanopore requires an external strength or component to transport dsDNA. The technical scheme in this invention to solve the above deficiency is to provide a truncated E1-1 (306-577) protein, an E1-2 (306-605) protein and its variant derived from bovine papillomavirus double-stranded DNA helicase protein, as well as a variant of its homologous protein which is used for preparing membrane containing conductive channel, providing a new and effective choice for this field.

Transmembrane nanopore with nucleic acid unwinding function and its construction methods and applications

The present invention belongs to the field of biological medicine, particularly to a novel tumor vaccine. In order to solve the problem in the art that no technical scheme is available for generating lasting and high-effective anti-tumor immune responses, the present invention provides a tumor vaccine mainly containing a complex as a main active ingredient, wherein the complex is formed by nucleic acid, especially replicable nucleic acid not expressing exogenous gene, and cationic biomaterial. The nucleic acid and the cationic biomaterial in the tumor vaccine according to the present invention have synergistic interactions on direct killing of tumor cells, and induction of the innate immune response and adaptive immune response of body against tumor. In addition, the prepared tumor vaccine has simple drug component and is easy to produce and maintain quality control. The tumor vaccine has a good prospect for application.

Tumor vaccine and uses thereof

Disclosed are a tumor biomarker and application thereof, and a tumor detection kit. Patients suffering from non-small cell lung cancer, containing an EML4-ALK or SLC34A2-ROS1 fusion gene, have a specific circular RNA in blood. The base sequences of the circular RNA are represented by SEQ ID NOS. 1-6. The circular RNA is associated with non-small cell lung cancer, stably and constantly exists in plasma samples, and has high specificity and effectiveness, and thus can be used as a biomarker for tumor detection. Reagents such as primers and probes for detecting the circular RNA can be used for preparing the tumor detection kit.

Methods of detecting an EML4-ALK fusion tumor biomarker

The disclosure in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the disclosure relates to gene transfer methods using the recombinant adeno-associated viruses. In some aspects, the disclosure relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same.

AAV capsid designs

The present invention relates to the field of tuberculosis vaccines, and specifically relates to a tuberculosis vaccine, a preparation method thereof, and a use thereof. To address the problem of existing vaccines being unsuitable for patients having weak immunity, the present invention provides a preparation method for a tuberculosis vaccine: first obtainingsingle cell bacteria, and using low dosage radiation to irradiate periodically thesingle cell bacteria, so as to obtain the tuberculosis vaccine. The present invention completely retains all of the antigen characteristics of the bacteria, and can more rapidly stimulate stronger specific immune responses, thereby achieving effective and long-lasting immunity. The vaccine prepared using the present invention has low toxicity, is rapid-acting and safer, and can be used for the prevention and treatment of tuberculosis for people having immunodeficiency.

Tuberculosis vaccine, preparation method therefor, and use thereof

The invention belongs to the field of biological medicine, in particular refers to an alhydrogel-sodium chloride compound immunologic adjuvant, preparation method and use thereof. The technical problem to be solved by the invention is to provide a well-behaved and novel immunologic adjuvant. The technical solution for solving the technical problem of the invention is to provide the use of sodium chloride in preparing immunologic adjuvant and the alhydrogel-sodium chloride compound immunologic adjuvant obtained on the basis thereof. The compound immunologic adjuvant mainly includes alhydrogel and sodium chloride. The alhydrogel-sodium chloride compound immunologic adjuvant of the invention is an excellent compound immunologic adjuvant, which can be used for various antigens, and provides a new and effective choice for the development and application of vaccines due to the advantages of simple and convenient use, low cost, strong immune activity, high clinical safety and the like.

Alhydrogel-sodium chloride compound immunologic adjuvant, preparation method and use thereof

The present invention pertains to the field of chemical medicine, particularly to 4-substituted coumarin derivatives and preparation methods and applications thereof. The invention provides 4-substituted coumarin derivatives with a structural formula as shown in Formula I. The invention also provides preparation methods and applications for the above 4-substituted coumarin derivatives. The compounds provided in the invention have strong anti-tumor activity with IC50 for plural tumor cell lines between 0.01-5 nM, and it also performs better to inhibit microtubule polymerization and has diversified biological activities and low toxicity, providing new options for drug-sensitive and drug-resistant tumor cells. 

4-substituted coumarin derivatives and preparation methods and uses thereof

The present invention relates to the field of chemical and medicine, more particularly, 3-ethynylpyrazolopyrimidine derivatives and their preparation methods and uses. The invention provides a 3-ethynylpyrazolopyrimidine derivative, and the structure is shown in formula I. The present invention also provides preparation methods and use of 3-ethynylpyrazolopyrimidine derivatives, comprising the compounds and derivatives, and their pharmaceutical compositions for the use of the treatment and prevention of tumors. 

3-acetylenyl-pyrazole-pyrimidine derivative, and preparation method therefor and uses thereof

The present invention relates to the field of the chemical medicines, and in particular, to purinyl-N-hydroxyl pyrimidine formamide derivatives, a preparation method therefor and a use thereof. The present invention provides a purinyl-N-hydroxyl pyrimidine formamide derivative having a structure represented by formula (I). The invention also provides a method for preparing said purinyl-N-hydroxyl pyrimidine formamide derivative and a use thereof. Purinyl-N-hydroxyl pyrimidine formamide derivative provided in the invention can be not only a PI3K and HDAC double-functional target kinase inhibitor, but also a PI3K or HDAC single target kinase inhibitor, thus providing new choice for preparing multi-target inhibitors. 

Purinyl-N-hydroxyl pyrimidine formamide derivative, preparation methods and uses thereof

A series of hepatitis C virus (HCV) inhibitors and compositions and applications thereof in the preparation of drugs for treating chronic HCV infection. Especially, a series of compounds that are used as NS5A inhibitors, and compositions and uses thereof in the preparations of drugs.

Hepatitis C virus inhibitors and uses thereof in preparation of drugs

Provided is a benzofuran analog having a structure represented by formula (I) and used as an NS4B inhibitor, or a pharmaceutically acceptable salt of the benzofuran analog. The benzofuran analog has anti-hepatitis C virus activity.

Benzofuran analogue as NS4B inhibitor

Growing community of inventors

Chengdu, China

Yuquan Wei